AR085249A1 - DERIVATIVES OF OXIMA AS GPR119 AGONISTS - Google Patents
DERIVATIVES OF OXIMA AS GPR119 AGONISTSInfo
- Publication number
- AR085249A1 AR085249A1 ARP120100513A AR085249A1 AR 085249 A1 AR085249 A1 AR 085249A1 AR P120100513 A ARP120100513 A AR P120100513A AR 085249 A1 AR085249 A1 AR 085249A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- optionally substituted
- alkyl
- cycloalkyl
- sulfur
- Prior art date
Links
- 229940100607 GPR119 agonist Drugs 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- 150000001412 amines Chemical class 0.000 abstract 4
- 229910052799 carbon Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 239000011593 sulfur Substances 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000002923 oximes Chemical class 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 abstract 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere a derivados de oxima de la fórmula (1), a un método para su preparación, a una composición farmacéutica que los contiene y al uso de los mismos. Los derivados de oxima de acuerdo con la presente actúan como agonistas de GPR119 para estimular la secreción de insulina y promover la formación de GLP-1 para la prevención o el tratamiento de la diabetes tipo 2, las complicaciones de la diabetes, la obesidad, la dislipidemia o la osteoporosis. En donde, RA, RB, n, Ar, A, B, R1 y R2 son como se definen en la presente.Reivindicación 1: Derivados de oxima de la fórmula (1), o sales o isómeros farmacéuticamente aceptables de los mismos, caracterizados porque: RA representa un cicloalquilo de 4 a 7 miembros parcialmente o completamente saturado; RB representa un heterociclo de 4 a 7 miembros parcialmente o completamente saturado, o un sistema de anillo fusionado [5.5], [5.6], [5.7], [6.6] ó [6.7] que consiste en dos anillos; R1 y R2 representan independientemente hidrógeno, halógeno o alquilo; n representa un entero de 0 a 10 en cada anillo; A representa nitrógeno o carbono; B es seleccionado entre el grupo de fórmulas (2), en donde: D representa carbono, nitrógeno, oxígeno o azufre; R3, R4 y R5 son independientemente hidrógeno o halógeno, o representan en cada caso arilo, arilalquilo, alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo o amina, opcionalmente sustituidos; con la condición de que, cuando D es oxígeno o azufre, ambos, R3 y R4, no existen; cuando D es azufre, R5 no es amina; cuando D es nitrógeno, R3 no existe; cuando D es carbono, dos grupos seleccionados entre R3, R4 y R5 están unidos entre si para formar un heterociclo o cicloalquilo de 3 a 7 miembros opcionalmente sustituido, o para formar un heteroarilo o arilo de 5 ó 6 miembros, opcionalmente sustituido; E, F, G, H e I representan independientemente carbono, nitrógeno, oxígeno o azufre para formar un heteroarilo o arilo de 6 miembros, o formar un heteroarilo o arilo de 5 miembros, opcionalmente benzo-fusionado, excluyendo uno de E, F, G, H e I; n representa un entero de 0 a 5; R6 es hidrógeno o halógeno; o representa alquilo, cicloalquilo, arilo, arilalquilo, heterocicloalquilo o heteroarilalquilo, opcionalmente sustituidos; o representa hidroxi o amina opcionalmente sustituidos con 1 ó 2 alquilo o arilo, en donde dos sustituyentes de amina están unidos entre sí para formar un heterociclilo de 3 a 7 miembros; J representa sulfonilo o alquileno C1-4, opcionalmente sustituido; R7 es hidrógeno o halógeno, o representa alquilo, cicloalquilo, arilo, heteroarilo o heterociclilo, opcionalmente sustituidos; y Ar representa heteroarilo o arilo, opcionalmente sustituido.This refers to oxime derivatives of the formula (1), a method for their preparation, a pharmaceutical composition containing them and the use thereof. Oxime derivatives according to the present act as agonists of GPR119 to stimulate insulin secretion and promote the formation of GLP-1 for the prevention or treatment of type 2 diabetes, complications of diabetes, obesity, dyslipidemia or osteoporosis. Wherein, RA, RB, n, Ar, A, B, R1 and R2 are as defined herein. Claim 1: Oxime derivatives of the formula (1), or pharmaceutically acceptable salts or isomers thereof, characterized because: RA represents a partially or fully saturated cycloalkyl of 4 to 7 members; RB represents a partially or fully saturated 4- to 7-membered heterocycle, or a fused ring system [5.5], [5.6], [5.7], [6.6] or [6.7] consisting of two rings; R1 and R2 independently represent hydrogen, halogen or alkyl; n represents an integer from 0 to 10 in each ring; A represents nitrogen or carbon; B is selected from the group of formulas (2), where: D represents carbon, nitrogen, oxygen or sulfur; R3, R4 and R5 are independently hydrogen or halogen, or in each case represent aryl, arylalkyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclyl alkyl or amine, optionally substituted; with the proviso that, when D is oxygen or sulfur, both R3 and R4 do not exist; when D is sulfur, R5 is not amine; when D is nitrogen, R3 does not exist; when D is carbon, two groups selected from R3, R4 and R5 are linked together to form an optionally substituted 3- or 7-membered heterocycle or cycloalkyl, or to form an optionally substituted 5- or 6-membered heteroaryl or aryl; E, F, G, H and I independently represent carbon, nitrogen, oxygen or sulfur to form a 6-membered heteroaryl or aryl, or form a 5-membered heteroaryl or aryl, optionally benzo-fused, excluding one of E, F, G, H and I; n represents an integer from 0 to 5; R6 is hydrogen or halogen; or represents optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heterocycloalkyl or heteroarylalkyl; or represents hydroxy or amine optionally substituted with 1 or 2 alkyl or aryl, wherein two amine substituents are linked together to form a 3- to 7-membered heterocyclyl; J represents sulfonyl or C1-4 alkylene, optionally substituted; R7 is hydrogen or halogen, or represents optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; and Ar represents heteroaryl or aryl, optionally substituted.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110014298 | 2011-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085249A1 true AR085249A1 (en) | 2013-09-18 |
Family
ID=46672795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100513 AR085249A1 (en) | 2011-02-17 | 2012-02-16 | DERIVATIVES OF OXIMA AS GPR119 AGONISTS |
Country Status (5)
| Country | Link |
|---|---|
| KR (1) | KR101456286B1 (en) |
| AR (1) | AR085249A1 (en) |
| TW (1) | TW201309639A (en) |
| UY (1) | UY33912A (en) |
| WO (1) | WO2012111995A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091739A1 (en) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK |
| SG10201900631TA (en) | 2014-08-01 | 2019-02-27 | Nuevolution As | Compounds active towards bromodomains |
| CN106632302A (en) * | 2016-12-15 | 2017-05-10 | 苏州汉德创宏生化科技有限公司 | Synthesis method of 1-(thiazole-2-yl)piperidine-4-ol |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302548D0 (en) * | 2003-02-04 | 2003-03-12 | Syngenta Participations Ag | Avermectins substituted in the 4"- and 4' -positions having pesticidal properties |
| JP2009525961A (en) * | 2006-01-20 | 2009-07-16 | シェーリング コーポレイション | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
| KR20110017431A (en) * | 2008-06-10 | 2011-02-21 | 아보트 러보러터리즈 | Novel tricyclic compounds |
-
2012
- 2012-02-14 TW TW101104637A patent/TW201309639A/en unknown
- 2012-02-15 UY UY33912A patent/UY33912A/en not_active Application Discontinuation
- 2012-02-16 WO PCT/KR2012/001185 patent/WO2012111995A1/en active Application Filing
- 2012-02-16 KR KR20120015736A patent/KR101456286B1/en active IP Right Grant
- 2012-02-16 AR ARP120100513 patent/AR085249A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012111995A1 (en) | 2012-08-23 |
| TW201309639A (en) | 2013-03-01 |
| KR101456286B1 (en) | 2014-11-03 |
| UY33912A (en) | 2012-09-28 |
| KR20120094859A (en) | 2012-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067475A1 (en) | NON BASIC S ANTAGONISTS OF THE RECEIVER OF THE CONCENTRATING HORMONE OF MELANINA 1 | |
| AR056511A1 (en) | DERIVATIVES OF 2-AMINOPIRIMIDINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HISTAMINE RECEIVER H4 | |
| PE20191744A1 (en) | TYROSINAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | |
| CY1118973T1 (en) | DERIVATIVES OF AMOID Benzoimidazole-carboxylic acid for the treatment of metabolic or cardiovascular diseases | |
| DOP2017000304A (en) | NEW HYDROXY ACID DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR086100A1 (en) | CHROMENONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR078786A1 (en) | CHROMENONE DERIVATIVES | |
| NI201500160A (en) | 11-HYDROXYL DERIVATIVES OF BILE ACIDS AND AMINO ACID CONJUGATES THEREOF AS MODULATORS OF THE FARNESOID X RECEPTOR | |
| PE20110835A1 (en) | PYRIDYLOXY-INHIBITORS OF VEGF-R2 AND USE OF THE SAME FOR THE TREATMENT OF DISEASES | |
| PE20181024A1 (en) | DERIVATIVES OF CYCLOHEXANE SUBSTITUTED WITH AMIDO | |
| CR20170590A (en) | NEW HYDROXY ACID DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR069510A1 (en) | ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10 | |
| AR055395A1 (en) | INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS | |
| AR079236A1 (en) | CYCLHEXAN DERIVATIVES AND USES OF THE SAME | |
| PE20201165A1 (en) | PYRIDAZINE 1,4-DISUSTITUTED ANALOGS AND METHODS FOR TREATING CONDITIONS RELATED TO SMN DEFICIENCY | |
| AR046964A1 (en) | AZABICICLIC HETEROCICLES AS CANABINOID RECEPTOR MODULATORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO METABOLIC AND FOOD DISORDERS. | |
| AR086357A1 (en) | INDAZOL DERIVATIVES ACTIVE SUBSTITUTES AS QUINASE INHIBITORS | |
| UY28578A1 (en) | AMIDA DERIVATIVES | |
| AR063602A1 (en) | DERIVATIVES OF SPIROINDOLINONE, PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM AND THEIR USE IN THE OBTAINING OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ONCOLOGICAL DISORDERS. | |
| UY33606A (en) | PIRAZINE DERIVATIVES AS ENaC BLOCKERS | |
| UY33483A (en) | ACIDS OF HYDROXYPHENYLHEXINOIC ARYLOXIALQUYLENE-REPLACED, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT. | |
| AR065098A1 (en) | DOSAGE REGIME FOR COMT INHIBITORS | |
| UY33485A (en) | ACID DERIVATIVES (2-ARYLOXYACETHYLAMINE) PHENYLPROPIONIC, PROCEDURES FOR THE PREPARATION AND USE OF THE SAME AS MEDICATIONS. | |
| PE20150623A1 (en) | MODULATORS OF THE COMPLEMENT ROUTE AND USES OF THEM | |
| PE20141352A1 (en) | PHENYL-3-AZA-BICYCLE [3,1,0] HEX-3-IL-METHANONES AND ITS USE AS A MEDICINAL PRODUCT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |